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Objective: To estimate preferences in relevant treatment characteristics evaluated by different 
groups involved in the management of patients with rheumatic diseases.
Subjects and methods: We surveyed patients with rheumatic diseases, and rheumatologists, 
nurses, and pharmacists with experience in treatment with/provision of biologic drugs for these 
patients. Through a discrete choice experiment, participants evaluated 16 possible scenarios in 
which pairs of similarly efficacious treatments were described with six characteristics: 1) fre-
quency of administration; 2) mode and place of administration; 3) manner, helpfulness, efficiency, 
and courtesy of health personnel; 4) frequency of reactions at the site of drug administration; 
5) severity of generalized undesired/allergic reactions; and 6) additional cost. The direction 
and strength of preferences toward each characteristic level and the relative importance of each 
characteristic were estimated through a random-effects conditional logistic regression model.
Results: In total, 513 patients, 110 rheumatologists, 51 nurses, and 46 pharmacists from 30 centers 
in Italy participated. Characteristics 3, 4, and 6 were the most important for every subgroup; 1 
was least important for patients and rheumatologists, 2 was least important for pharmacists, and 
2 and 5 were least important for nurses. For characteristic 2, pharmacists preferred subcutaneous 
self-injection with a syringe; nurses preferred assisted infusion at an infusion center close to the 
patient’s home; patients and rheumatologists preferred subcutaneous self-injection with a pen.
Conclusion: The different preferences for some characteristics shown by the different groups 
can play an important role, together with purely clinical aspects, in the choice and consequent 
benefit of treatments, contributing also to a more satisfactory use of resources.
Keywords: preferences, biologic drugs, rheumatoid arthritis, ankylosing spondylitis, psoriatic 
arthritis, decision making
Introduction
Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) are 
among the most burdensome rheumatic diseases (RDs). They are chronic, progressive 
inflammatory conditions associated with severe morbidity and decline in functional 
status leading to a significant impairment of patients’ quality of life, limitations in 
activities, and restrictions in performance of social roles.1–4 At the societal level, the 
impact of these conditions includes high socioeconomic direct and indirect costs 
associated with increased use of health care resources, physical impairment, loss of 
working days, loss of efficiency at work, or loss of employment.5–8
Traditionally, drug management of RDs has included symptom-modifying therapies, 
mainly nonsteroidal anti-inflammatory drugs and corticosteroids, combined with 
disease-modifying antirheumatic drugs (DMARDs). Since the introduction of biologic 
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agents, particularly anti-tumor necrosis factor α agents, 
outcomes for these diseases have changed: the addition of 
biologic agents to treatment strategies has improved the 
ability to control disease activity and slow the progression of 
joint damage, with significant improvements in symptoms, 
function, and quality of life.9,10
Despite the widespread availability of biologics, particu-
larly the anti-tumor necrosis factor α agents, patient access to 
these agents differs significantly between countries. Potential 
barriers influencing availability may partly be explained by 
economic factors. Clinical practice also plays a key role in 
biologic access, and selecting the best treatment for each 
patient has become a challenging process for rheumatolo-
gists as well as payers.7,11 In agreement with the recently 
published recommendations of the European League Against 
Rheumatism for the management of RA with DMARDs,12 no 
evidence-based guidance is available for rheumatologists to 
preferentially prescribe a specific biologic drug, since direct 
comparisons between these agents at the start of treatment 
are lacking.
Recommendations for PsA13,14 have also been published 
recently to help clinicians in everyday practice manage 
patients treated with biologics. According to these recom-
mendations, choosing a biologic over another drug should 
be guided by aspects such as safety, individual patient char-
acteristics, patient preferences,15–22 and costs.23,24 However, 
management of patients with RDs involves a complex 
interaction between different parties, including patients, 
physicians, pharmacists, and nurses, each having a different 
but important role in the decision-making process. In the 
Italian health care system, for instance, physicians prescribe 
treatment after understanding each patient’s characteristics 
and needs, pharmacists interact with physicians to manage 
drugs provision according to requests and hospital budget, and 
nurses assist patients and interact with physicians to optimize 
treatment administration. Each group has their own set of 
preferences, influenced by the role they play in the health 
care system, their experiences, and their expectations.
Recent studies have shown that patients, physicians, 
budget holders, and other individuals involved do not neces-
sarily agree on the importance of some aspects of possible 
treatment options.21,22,24–29
Reaching an optimal decision requires being informed 
and aware of the opinions and preferences of all interested 
parties. Understanding the similarities and discrepancies in 
treatment preferences of the different individuals involved 
can be useful for improving the communication between 
them to uncover alternative approaches to treatment strategy, 
with positive effects on patient satisfaction, compliance, 
and, consequently, the effectiveness and efficiency of the 
treatments. In RDs, comparisons of preferences between 
patients and physicians have been reported,26,28,29 but other 
parties involved in the decision-making process can further 
influence the choice of therapy.
The objective of the Conjoint Analysis in Rheumatic 
Diseases (CARA) study was to compare the preferences 
of patients, rheumatologists, nurses, and pharmacists in the 
choice of treatment with biologics used in RA, AS, and PsA.
Subjects and methods
A multicenter stated preference study was conducted, based 
on a discrete choice experiment (DCE), a type of conjoint 
analysis.30,31 DCEs are based on the idea that goods or services 
(called “items”) can be described by their characteristics 
(or attributes) and individual preferences for these items are 
dependent on the levels of their characteristics. Within a 
DCE, hypothetical scenarios are created with combinations of 
previously selected characteristic levels; these are presented 
to participants who choose between alternative options. 
DCEs make it possible to estimate whether a characteristic 
level is important, to compare the relative importance (RI) 
of one characteristic with others, and to determine how 
individuals are willing to trade between different character-
istic levels, by estimating the marginal rate of substitution. 
If a cost characteristic is included in the choice sets, the 
marginal rate of substitution can be expressed in monetary 
terms, that is, in terms of willingness to pay (WTP) for a 
characteristic level.
The present DCE study, designed according to current 
guidelines32 and experience gained from previous research in 
the Italian health care system,25,26,33,34 was conducted in four 
main phases: 1) design of the DCE, consisting of choosing 
characteristics, assigning levels to each characteristic, and 
constructing the scenarios to be evaluated; 2) development 
of the survey instrument; 3) data collection; and 4) data 
analysis and interpretation of results. Details of the design 
process are reported in the Supplementary material. Table 1 
lists the final characteristics and the levels selected. Particular 
attention should be paid to the cost characteristic, which we 
introduced as the possibility of increasing health care taxes 
for any citizen. In the Italian health care system, especially 
for expensive treatments such as biologics, this approach is 
more realistic than focusing on the price of the product or the 
cost of treatment, which is entirely paid by regional health 
services, and indirectly by citizens through taxes.27 The levels 
for the cost characteristic were decided by considering that 
the actual costs paid as health care taxes by Italian citizens 
correspond to a per capita monthly cost of €130 over a per 
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capita gross income of €1,700 (corresponding to 8% of the 
gross income).27 Accordingly, we introduced the following 
three levels: 1) no increase in health care taxes to be paid 
(reference level); 2) health care taxes are twice those cur-
rently paid; and 3) health care taxes are three times those 
currently paid (details in Table 1).
Sixteen pairwise choice sets were generated, which 
demonstrated to be a reasonable number for evaluation by 
each respondent.27,33
Each choice set (example in Figure 1) required choosing 
between two treatment options described by six character-
istics with different levels. At the top of each scenario, a 
reminder that the two treatments must be assumed to be 
equivalent in clinical effectiveness was included, considering 
that clinical effects are similar for the different biologics. This 
was to guide the respondent to focus on characteristics other 
than clinical effectiveness, which was found to potentially 
dominate participant preferences, as confirmed by recent 
research.24
survey instrument and data collection 
process
A paper questionnaire for self-completion was prepared and 
validated in a subgroup of participants. It included 16 choice 
sets and a number of other items identified as relevant to 
the study. In their questionnaires, physicians, nurses, and 
pharmacists gave some information on their sociodemo-
graphics and experience of biologic treatment. In patients’ 
questionnaires, physicians reported data on their clinical 
condition, and patients specified their sociodemographic 
characteristics and health-related quality of life using the 
EQ-5D-5L.35 These results are not reported in this paper, 
which focuses on preferences. In all the questionnaires, we 
included detailed descriptions of meanings of the character-
istics and levels, and instructions on how to perform the exer-
cise. To avoid a possible order effect on answers, we changed 
the order of the choice sets. All data were collected during 
routine practice. The questionnaire had to be completed 
independently at the hospital; however, a physician or nurse 
was on hand to address any uncertainties about the content.
Participants and setting
To obtain results that reflect the whole Italian health care 
system, we chose 30 key Italian university and hospital 
rheumatology centers from different regions of Northern, 
Central, and Southern Italy. Participants included patients, 
rheumatologists, nurses, and pharmacists involved in 
treatment with or management of biologics, who met the 
following inclusion criteria. Patients had to be $18 years 
old, recruited consecutively during a routine visit, and with 
a diagnosis of RA, AS, or PsA. Within each diagnosis, 
around half, classified as “naïve”, had no previous or current 
Table 1 characteristics and levels for the discrete choice experiment scenarios
Characteristic Levels
Frequency of administration 1. Once every 7–15 days (FreQ1)
2. Once every 1–2 months (FreQ2)
3. Once every 6 months (FreQ3)
Mode and place of administration 1. subcutaneous self-injection with pen at home (ADM1)
2. subcutaneous self-injection with a syringe at home (ADM2)
3. infusion, assisted by a nurse or doctor, at an infusion center close to 
home (ADM3)
4. infusion assisted by a nurse or doctor, at the rheumatology center 
(ADM4)
Manner, helpfulness, efficiency, and courtesy of health personnel  
(doctors, nurses) who assist the patient during treatment and  
related aspects (eg, side effects) and during follow-up visits
1. Unsatisfactory for the patient (cOMFOrT1)
2. Fairly satisfactory for the patient (cOMFOrT2)
3. Very satisfactory for the patient (cOMFOrT3)
Frequency of reactions at the site of drug administration  
(eg, erythema, irritation, burning, pain at the injection site)
1. infrequently, that is, #3 times a year (lOcAlr1)
2. Frequent, $4 times per year (lOcAlr2)
generalized undesired reactions or allergic reactions involving  
the whole body, due to the administration of the biologic drug
1. Mild, such as redness, tightness of the throat, headache (generAlr1)
2. serious, such as severe discomfort, shortness of breath, hypotensive 
shock (fainting) (generAlr2)
Additional cost to be paid 1. none (taxes for health care remain the same already paid) (cOsT1)
2. health care taxes are doubled (€130 more per month on an assumed 
€1,700 of gross income) (cOsT2)
3. health care taxes are tripled (€260 more per month on an assumed 
€1,700 of gross income) (cOsT3)
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experience of treatment with biologics; however, at the time 
of recruitment, they had to be eligible for and were prescribed 
with a biologic. The other half of the patients were “experi-
enced”, having received at the time of recruitment or during 
the previous 12 months and for $3 months treatment with a 
biologic for their RD. Patients were not recruited if they did 
not meet the inclusion criteria, were unable to understand 
or carry out the required tasks, were on a clinical trial of an 
investigational or marketed product, or had contraindications 
for use of any biologic. Rheumatologists and nurses had to 
operate in the Italian health care system, and have experience 
in treating the target patients with biologics (ie, managing at 
least ten patients per month treated with biologics for RA, 
AS, and/or PsA). Pharmacists were included if they were 
involved in managing and delivering biologics for RA, PsA, 
and/or AS in the center’s pharmacy.
The sample size of each subgroup was determined 
according to a formal calculation,36 with some practical 
considerations, clarified in the Supplementary material. 
Accordingly, we had to recruit ~90 patients in each subgroup 
of diagnosis (RA, AS, SpA) and treatment experience (naïve 
and experienced), for a total of up to 540 patients, ~100 
rheumatologists, ~50 pharmacists, and ~50 nurses. The study 
was conducted in agreement with National Regulatory 
Requirements, International Conference on Harmonization 
Guidelines for Good Clinical Practice, and the 18th World 
Medical Assembly37 and all subsequent amendments. The 
ethics committees of the participating rheumatology cen-
ters accepted the study protocol. Participants had to sign an 
informed consent form, after receiving information on the aim 
of the study, type of data, and method of data collection.
Data analysis
Before conducting the statistical analyses, we assessed 
reliability of the data by checking if any respondent had 
answered fewer than half of the 16 choice scenarios, or if 
they had always chosen the same option (eg, always treat-
ment A), as indicators of non-understanding or performing 
the task without due attention.
Responses from the DCE were analyzed according to 
the random utility theory,38 using a random-effects condi-
tional logistic regression model, which allowed for mul-
tiple observations from individuals, in STATA program 
(Version 12).
The systematic utility V of each treatment option j was 
estimated as a linear and additive function of treatment 
Figure 1 An example of a choice set used in the discrete choice experiment.
Notes: Participants received 16 choice sets, in which only the combination of levels was changed. A reminder above each choice set specified that the two treatment 
options had to be considered as equal in terms of clinical effectiveness. characteristics were listed on the left of each choice set and the two columns on the right presented 
combinations of levels to describe and compare two possible treatment options.
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characteristics and levels included in the choice sets analyzed 
(Equation 1):
Vj =  β
1
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(1)
Each regression coefficient β corresponds to the param-
eter estimates indicating the direction (ie, whether a char-
acteristic level is more or less preferred) and the strength 
(ie, the dimension of the estimate) of preference for one 
level (eg, β
2
 for frequency of administration of once every 
1–2 or every 6 months) compared with the reference level 
(eg, β
3
 for once every 7–15 days). The 95% CIs and the 
P-values for the characteristic levels are calculated to show 
the statistical significance of the parameter estimate of the 
corresponding level compared with the reference level. In 
particular, where CIs do not include the 0 value and when 
those of different levels of a particular characteristic do 
not overlap, it means that the mean estimates are different 
from 0 and from each other at the 5% level of statistical 
significance.
To understand which characteristic contributes more 
to the utility of treatment options under study, its RI was 
estimated by computing the ratio of the utility given to each 
characteristic (within the range of the levels assigned) to 
the sum of the utilities assigned to the level ranges of all 
characteristics included in the experiment.
We calculated the WTP in terms of increased health care 
taxes for the respondents, in order to improve, ceteris paribus, 
by one level the benefit of a specific treatment characteristic 
for all patients in the target health care system (eg, the amount 
of increased taxes that participants are willing to pay, so that 
all target patients receive a treatment administered once every 
1–2 months instead of once every 7–15 days). WTP can be 
calculated as in Equation 2.
 
WTP =
β
−β
x
cost  
(2)
To calculate 95% CIs for WTP estimates, a nonparametric 
bootstrapping approach was used39 with 500 iterations 
for each WTP estimate. The results of the analyses were 
considered statistically significant if P,0.05, with two-
tailed tests.
The analyses were conducted by splitting the sample 
into four subgroups to identify and investigate the different 
preferences between patients, rheumatologists, nurses, and 
pharmacists.
Results
characteristics of participants
Overall, 720 individuals evenly distributed within different 
areas of Italy (71.3% were patients, 15.3% rheumatologists, 
7.1% nurses, and 6.4% pharmacists) participated in the study. 
Data were collected from the rheumatology centers in 17 of 
20 regions of Italy between July 2014 and December 2015. 
Compared with the Italian general population aged $18 years 
(men, 47.9%; mean age, 50.7 years),40 each subgroup had 
fewer men (42.5% of patients, 40.0% of rheumatologists, 
13.7% of nurses, and 23.9% of pharmacists), whereas the 
mean age was equal for patients (50.0±13.6 years) and 
lower for other participants (43.7±10.5, 46.0±7.8, and 
39.8±8.6 years for rheumatologists, nurses, and pharmacists, 
respectively). Table 2 shows the education level, working 
status, and clinical characteristics of patients. As planned, 
patients were balanced by diagnosis of RA, PsA, and AS and 
their experience with biologic treatment. Patients reported 
an average of 10.8 years since the appearance of first symp-
toms and 8 years since the first diagnosis of their disease. 
Overall, ten biologic drugs were used, more frequently for 
effectiveness not reached with previous treatments. Before 
the biologic treatment currently taken or prescribed, the 
patients had been treated with $1 drug treatment among 
methotrexate, DMARDs, nonsteroidal anti-inflammatory 
drugs, corticosteroids, or a different biologic drug.
Analysis of preferences
From our data quality check, responses of preferences for 
five participants (patients) were excluded from the analysis, 
as they were not considered reliable. Therefore, results from 
715 participants (508 patients) are included.
Generally, for RI assigned to each characteristic (Figure 2), 
the most important characteristics were “frequency of reac-
tions at the site of drug administration” (26.9%–45.8% of 
importance relative to other characteristics); “additional cost” 
as health care taxes (23.0%–35.2%); and “manner, helpfulness, 
efficiency, and courtesy of health personnel” (13.2%–26.1%). 
“Frequency of administration” was the least important for 
patients and rheumatologists (,2%); “mode and place of 
administration” was least important for pharmacists (1.1%); 
and “mode and place of administration” and “generalized 
undesired reactions or allergic reactions involving the whole 
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body” were the least important for nurses (,5% for each). 
“Frequency of administration” was considered relatively more 
important by nurses (9.5%) than other participants.
All the following results on direction and strength (using 
the statistical significance if CIs do not overlap with estimates 
of the other levels in the same characteristics) of preferences 
and on WTP within each characteristic must be considered 
ceteris paribus. All subgroups preferred a lower frequency of 
administration (Figure 3); however, a frequency of once every 
1–2 months was preferred to once every 6 months (statistically 
significant for patients, pharmacists, and nurses), which was 
significantly preferred to once every 7–15 days by patients and 
nurses. Preferences for the mode and place of administration 
were different between subgroups, but statistically significant 
only for patients, who preferred subcutaneous self-injection 
with pen at home to any assisted mode of administration. 
Every subgroup was considered significantly important: a 
fairly or very satisfactory level of support from health person-
nel who assist patients with their treatment; mild, generalized, 
undesired, or allergic reactions to the whole body; and not 
paying twice or three times the health care taxes to make the 
described treatment available to patients.
The estimated mean WTP was similar among the four 
subgroups; however, it was significant only for patients and 
some of the pharmacist responses (Table 3). In particular, 
the highest significant mean WTP was estimated for mild 
vs severe generalized undesired or allergic reactions among 
patients, corresponding to €391 per month. The second highest 
mean WTP was estimated for having a very satisfactory level 
of support from the health personnel, which reached up to 
€258 per month among nurses, but was statistically significant 
only among patients and pharmacists with about €130–170 
per month. However, a significant WTP among patients and 
pharmacists was estimated also for a fairly satisfactory level 
of support, corresponding to about €83 and €95 per month, 
respectively, and reaching almost €123 per month among 
nurses, although not significant from a statistical perspec-
tive. The third highest mean WTP was estimated for a treat-
ment administered every 1–2 months instead of every 7–15 
days, reaching up to €79 per month among nurses, but being 
significant only for patients and pharmacists with €65 and 
€75 per month, respectively. Then, patients would pay on 
average an additional €45–50 per month to have a treatment 
subcutaneously self-administered with a pen at home (since 
this was included as a reference, negative WTP estimates were 
produced in the other levels), instead of a treatment requiring 
assisted infusion at the infusion center or the rheumatology 
Table 2 Patients characteristics
Variables Values
education, no (%)
none (,5 years of primary school)
Primary school (5 years)
lower secondary school (3 years)
Upper secondary school (4–5 years)
graduate (4–6 years)
Post-graduate ($3 years’ specialization/doctorate)
7 (1.4)
58 (11.3)
137 (26.7)
210 (40.9)
84 (16.4)
14 (2.7)
Working status, no (%)a
Paid work
retired
housewife
Unemployed
student
Unpaid work (eg, volunteer)
272 (54.4)
100 (19.8)
72 (14.3)
47 (9.3)
10 (2.0)
3 (0.6)
Diagnosis, no (%)
rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
174 (33.9)
179 (34.9)
160 (31.2)
Years from the appearance of first symptoms
Mean (sD)
Median (min–max)
10.8 (9.4)
8.0 (0.2–50.0)
Years from diagnosis
Mean (sD)
Median (minb–max)
8.0 (8.2)
5.0 (0–43.0)
experience with biologic treatment, no (%)
With experience and currently treated
With experience, but currently not treated
naïve (ie, never treated before and with a new  
prescription)
262 (51.1)
8 (1.5)
243 (47.4)
Biologic drugs used or prescribed, no (%)
Abatacept
Adalimumab
certolizumab
etanercept
golimumab
Infliximab
rituximab
Tocilizumab
Ustekinumab
Other (not specified)
38 (7.4)
105 (20.5)
31 (6.1)
88 (17.2)
90 (17.6)
99 (19.3)
12 (2.3)
42 (8.2)
6 (1.2)
1 (0.2)
reason for starting treatment with biologic drugs,  
no (%)c
no effectiveness of previous treatment
no tolerance to previous treatment
side effects from previous treatment
Other reasons
478 (93.2)
60 (11.7)
26 (5.1)
9 (1.8)
Treatment before biologic drugs, no (%)c
Methotrexate
$1 DMArD (not MTX)
nsAiDs
corticosteroids
Biologic drug
316 (61.6)
203 (39.6)
268 (52.2)
231 (45.0)
102 (19.9)
Notes: aThe main work activity was considered, each patient was included in only 
one category. bTwo patients were diagnosed ,1 month before enrollment. cMore 
than one reason could be reported.
Abbreviations: DMArD, disease-modifying antirheumatic drug; MTX, metho-
trexate; NSAIDs, nonsteroidal anti-inflammatory drugs.
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center. A mean WTP, albeit not statistically significant, of 
about €42–68 per month was estimated among nurses. A mean 
WTP corresponding to up to €82 per month was estimated 
among the four groups for infrequent local reactions, but it was 
significant only for patients with almost €45 per month.
Discussion
Although the literature reports studies in which patients’ 
and physicians’ opinions were compared, to the best of our 
knowledge, this is the first study showing how four different 
groups of individuals involved in different ways in treating 
patients with RDs or managing biologics can disagree on the 
RI of some characteristics of treatment.
In particular, when looking at the RI of the six character-
istics included in the DCE, pharmacists, patients, and physi-
cians considered “frequency of reactions at the site of drug 
administration” and “additional cost” to be the most impor-
tant characteristics. For nurses, “manner, helpfulness, and 
efficiency of health personnel” was equally as important as 
the two characteristics above. In contrast, this characteristic 
was less important for the other subgroups, since according 
to their responses, we ranked it third in importance. This 
disagreement between nurses and the other participants can 
be attributed to a better knowledge and awareness of this 
process characteristic, compared with physicians and phar-
macists, because of nurses’ experience in assisting patients 
at the centers during treatment administration and routine 
visits. A higher agreement may be expected between patients 
and nurses, since they are in close relationship; instead, we 
found that patients were more concerned than nurses about 
the severity of possible generalized undesired reactions.
When looking at the strength of preferences, as expected, 
every subgroup assigned a statistically significant higher 
preference to “fewer local undesired reactions”, “mild 
generalized undesired reactions”, and “no additional cost to 
pay”. Furthermore, every subgroup assigned a significantly 
higher importance to a satisfactory level of helpfulness from 
health personnel. However, only patients assigned a statisti-
cally significant lower preference for triple compared with 
double additional costs, and a higher desirability for a very 
satisfactory compared with a fairly satisfactory service. For 
the frequency of administration, every subgroup considered 
having one administration every 1–2 months preferable, 
although this higher preference was only statistically sig-
nificant in patients and physicians. For the mode and place 
of administration, only patients assigned a significantly 
higher preference to having an assisted infusion compared 
with a subcutaneous self-injection. WTP was statistically 
significant for patients in all the characteristics (although 
not all the levels) and for pharmacists in support of health 
personnel and generalized undesired or allergic reactions, 
although several WTP amounts estimated for these subjects 
were similar to those of the other groups of respondents. 
This apparent inconsistency between amount and statistical 
significance of WTP estimates in the different groups of 
participants can be attributed to the fact that estimates from 
the patients are more precise, as shown with the smaller CIs, 
since they are derived from many more observations (.8,000 
choices from 16 choice sets answered by 513 patients) than 
those from the other subgroups (1,700 from the rheumatolo-
gists, about 800 and 700 from the nurses and pharmacists, 
respectively). Hence, we could consider the nonsignificant 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Patients Rheumatologists Nurses Pharmacists
Additional cost 30.1% 23.0% 28.5% 35.2%
Generalized undesired reactions or allergic reactions 4.9% 8.4% 4.4% 6.3%
Frequency of reactions at the site of drug administration 42.2% 45.8% 26.9% 41.1%
Manner, helpfulness, efficiency and courtesy of health personnel 17.0% 17.4% 26.1% 13.2%
Mode and place of administration 4.4% 3.8% 4.6% 1.1%
Frequency of administration 1.4% 1.7% 9.5% 3.1%
Figure 2 relative importance of each characteristic to patients, rheumatologists, nurses, and pharmacists.
Notes: each column shows the ri estimated from the preferences elicited by each subgroup. Within each column, the height of the differently colored areas shows the 
amount of ri of each characteristic compared with the others.
Abbreviation: ri, relative importance.
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results with relatively high WTP estimates also potentially 
relevant. The highest WTP was estimated for mild gener-
alized undesired or allergic reactions, followed by a very 
satisfactory support by the health personnel. Interestingly, 
among the patients only (as shown by not overlapping CIs 
of these estimates), we also found a significantly higher 
WTP for very satisfactory vs fairly satisfactory support by 
the health personnel, showing the high importance assigned 
by patients to this characteristic, which was specifically 
requested to be included in the choice tasks incidentally 
during the preliminary study.
In other countries, several studies have been conducted 
in recent years on preferences of patients with RDs,15–19 
while others have also involved the perspective of rheuma-
tologists toward different aspects of drug treatments, with 
or without biologics.24,26,41–46 These studies used different 
methods than ours, so results cannot be directly compared. 
For instance, in the recent study by Nolla et al,26 only patients 
and physicians were involved and only four characteristics 
were used to describe possible treatment options, of which 
only administration method and risk of adverse events were 
included in our study. In addition, a full-profile ranking 
exercise was used, that is, treatment options were ordered 
from most to least important, whereas our exercise consisted 
of a series of pairwise choices between two options each. 
Although we cannot directly compare results, we can make 
some general comparisons. First, both studies indicate that 
patients and rheumatologists have similar preferences: in 
our study, both the RI of each characteristic and the strength 
of preferences assigned to the single characteristic levels 
were more similar between patients and rheumatologists 
than pharmacists or nurses. Second, in the Spanish study, 
both patients and rheumatologists significantly preferred 
subcutaneous self-injection at home to intravenous admin-
istration by a health care professional at the hospital; our 
study showed a similar result among patients, but physi-
cians as well as pharmacists were not concerned about this 
characteristic. Nurses were shown to be in favor of assisted 
infusion, although the strength of these preferences was not 
statistically significant.
Other studies available in the literature underline the 
importance of preference for route and place of admin-
istration as potentially influencing the acceptance of and 
adherence to treatment.42,44–46 In a study conducted in 
Italy some years ago,45 it was reported that intravenous 
administration was preferred for safety, rapidity, and reas-
surance, whereas the subcutaneous route was preferred for 
convenience. The authors of a study conducted in France42 
found that almost half of the patients among those using 
intravenous administrations preferred to keep this route. 
The authors interpreted these results as a patient’s need for 
reassuring medical assistance and hospital administration, 
in apparent contrast to available evidence demonstrating a 
similar safety profile of the two modes of administration, 
suggesting that patients are probably given insufficient 
information about this.
Results from a systematic review conducted by the Italian 
experts show how the benefit of treatment with biologic drugs 
in patients with RA, PsA, and AS can significantly depend 
on patient satisfaction and compliance with treatment, and 
knowledge on reason of discontinuation together with appro-
priate awareness of patients’ characteristics may contribute 
to achieve good results.20 In their systematic review focus-
ing on patient-reported outcomes in subjects with AS and 
PsA, Torre-Alonso et al underlined that the clinical benefits 
of biologic treatments demonstrated in randomized clinical 
trials may actually be reduced by poor compliance and early 
discontinuation in clinical practice, with the consequent 
need for more aggressive treatments and increase of costs.22 
Therefore, considering patients’ preferences and involving 
them in the treatment decision making through a satisfac-
tory communication process with clinicians can have posi-
tive implications on patients’ satisfaction, compliance, and 
benefits from treatment, and can reduce unnecessary costs. 
With the CARA study, we show that other subjects involved 
in the process can have their own preferences that differ from 
those of patients and clinicians, such as nurses who assist 
patients during treatment administration and even pharma-
cists who interact with clinicians for the management of the 
hospital budgets allocated for drugs delivery, showing how 
their interactions can contribute further in the final decisions.
The importance attributed to the cost of treatment has 
been investigated in a DCE study in which 559 rheumatolo-
gists from 12 European countries, including Italy, partici-
pated to assess the value assigned to some characteristics of 
treatment used in patients with RDs.43 Participants showed 
willingness to trade between treatment efficacy, safety, 
and patient preference, as they would not choose a treat-
ment not preferred by patients, and costs. In our study, all 
participants valued the cost characteristic included in the 
scenarios, proving they can take this aspect into account 
when evaluating different treatment options. It is important 
to note that preferences for treatment cost could also depend 
on the type of health care system, especially on the entity, 
that is, national health service, health insurance, or patient 
pays for the treatment, with consequent different impacts on 
individual perceptions and opinions. To present the scenarios 
realistic for our context, we used as a cost characteristic the 
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possible increase of health care taxes for any citizen, that 
is, potentially including all the participants in the study, 
to ensure the availability of the described treatment to all 
the target patients, which could not be applicable in other 
contexts. However, although the CARA study may not 
strictly apply in all other health care systems, it shows how 
different and not necessarily as expected can be the prefer-
ences of the different parties involved in the prescription, 
use, and payment for biologic treatments and can guide the 
optimization of benefits and a more efficient use of resources 
attributable to them.
Conclusion
While all respondents agreed on the preferences assigned 
to some characteristics, they did not agree on others. The 
results of the present study are useful to understand which 
treatment characteristics could influence the behavior of dif-
ferent persons, according to their role and perspective, and 
related consequences on treatment satisfaction, compliance 
and final benefits for patients, together with the overall costs 
for the whole health care system.
For many years, decisions on health technologies have 
been mainly physician centered; instead, observations 
derived from patients and the different health care profes-
sionals may be helpful in modifying the perspectives of the 
decision-making process. Scientific studies estimating and 
comparing preferences between different parties constitute 
an important opportunity to provide useful information 
for guiding interactions and decisions at different levels: 
physician–budget holder, nurse–physician, nurse–patient, 
and patient–physician. Taking into account the results of the 
CARA study could guide the conduct of good choices aimed 
at optimizing benefits and efficiently allocating resources.
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Supplementary materials
Details of the discrete choice experiment 
and study design
Overview of the discrete choice experiment 
technique
The discrete choice experiment (DCE) is a technique for 
eliciting preferences and a useful tool widely employed for 
estimating values of non-market goods and services. As the 
DCE elicitation process consists of a trade-off between 
characteristics during the decision-making process, it has 
the potential to meet the economic criteria for measuring 
benefit. In the past 20 years, DCEs have been increasingly 
used to elicit preferences for health care interventions and 
to allow inclusion of more than just health outcomes.1 
A number of publications are available on DCEs applied in 
rheumatology.2–5
To conduct such a study, a series of steps included in 
two main phases were carried out. Importantly, to obtain 
an efficient set of choice sets, both the number and type of 
characteristics and levels had to be selected carefully, since 
the dimension and, hence, the complexity of the experimental 
design exponentially increase with the number of these ele-
ments, with possible negative effects on the capability of the 
tasks to capture all the information of interest.
The first phase consisted of designing the DCE and is 
described below; the second phase consisted of recruiting 
the participants, collecting and analyzing the data, and inter-
preting the results. 
Design of the Dce
The design of the present DCE consisted of three steps: 
1) identifying and selecting the characteristics and assigning 
levels to each characteristic; 2) constructing the scenarios to 
be evaluated; and 3) developing the survey instrument. 
1. Identification and selection of characteristics and 
levels 
 We conducted a review of the literature to identify the 
attributes of treatments potentially relevant for the tar-
get population. Then, within a focus group with expert 
rheumatologists (n=3) and patients with all three target 
conditions (n=9), we identified the final set of attributes 
and related levels.
2. Construction of the scenarios to be evaluated
 A fractional factorial experimental design was used to 
define the scenarios of treatments to be evaluated. The 
factorial approach consists of combining every attribute 
level to create possible treatment options. However, a 
full factorial design would generate too many scenarios 
to be valued, implying a too high cognitive burden to 
the participants. In particular, in the present study, we 
obtained the combination 33*41*22, which would pro-
duce 432 possible treatment options, corresponding to 
186,192 possible scenarios of two options each. Hence, 
a fraction of all the possible scenarios had to be selected 
in a way that also guaranteed statistical efficiency of the 
design to obtain reliable estimates of preferences. In this 
study, with an orthogonal statistically efficient design,6 
we selected 16 treatment descriptions suitable for main 
effects estimations. The 16 profiles were then paired to 
others by applying a fold-over approach to ensure a mini-
mum overlap between levels within $1 characteristics, so 
that the respondents would make choices by evaluating 
every characteristic. Sixteen pair-wise choice sets were 
finally produced.
3. Development of the survey instrument
 Together with rheumatologists, we developed the ques-
tionnaire including the choice sets, information, and 
instructions on how to interpret the choice set and how 
to complete the task, and the other questions considered 
relevant to be collected during the study (details in the 
main paper). Subsequently, we tested the questionnaire 
within a pilot study involving nine patients, two pharma-
cists, and three nurses. These participants autonomously 
completed the questionnaire and then underwent a 
telephone interview to complete a cognitive debriefing. 
We assessed the feasibility, acceptability, and validity 
of the questionnaire. The results of the pilot study were 
discussed with the physicians, small changes were made, 
and the questionnaire was finalized for the data collection 
process.
sample size calculation
The sample size for each subgroup of participants was 
decided according to a formal calculation and some practical 
considerations. Basically, the sample size was determined by 
the desired level of accuracy of the estimated probabilities 
of choosing one of two treatment options. In particular, we 
applied the following formula:7,8
 
n 
q
Spa
 
2
2
Φ −−1 1
2
α






  
where: 
• n is the minimum sample size of respondents; 
• p is the true choice proportion of the relevant population 
for an alternative. We used the results of the pilot study 
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previously conducted, corresponding to a mean P=0.54 
(0.33–0.69); 
• q is defined as 1–p, hence q=0.46;
• [Φ-1 (1-α/2)] is the inverse cumulative distribution func-
tion of a standard normal distribution (ie, N~(0,1)) taken 
at (1-α/2);
• a is the level of allowable deviation as a percentage 
between the estimated p and the true choice proportion 
p. To apply it in this study, we considered two levels of a 
using our results from the pilot study. Since we had data 
from the pilot study for nine patients, two nurses, and 
three pharmacists, we considered the estimate of choice 
probability for health professionals weaker than that for 
patients. Accordingly, for patients, we used a=5% and 
for health professionals, we used a=6%; and
• S is the number of choice tasks per respondent, which 
we decided to be 16.
Accordingly, the formula gave the following n (minimum 
sample sizes) in each subgroup:
• Patients with each diagnosis in each treatment situation 
(experienced vs naïve)=82. We planned to receive data 
from 90 patients accounting for possible missing data.
• Nurses=48. We planned to receive data from 50 nurses 
accounting for possible missing data.
• Pharmacists=48. We planned to receive data from 
50 pharmacists accounting for possible missing data.
• Physicians=48. However, we planned to receive data 
from 100 physicians, for some practical considerations. 
Although all physicians are specialists in rheumatology 
in the key centers identified for this study, each phy-
sician generally focuses on one category (disease 
condition) of patients. Consequently, we decided to 
involve $3 clinicians from each center to recruit all the 
target patients. Therefore, they were also involved in the 
completion of the questionnaire, since this allowed us to 
obtain, for a relatively small additional effort, preferences 
data from a sample of physicians that overall was bal-
anced in terms of specific experience. We did not apply 
this to nurses or pharmacists, who were more homoge-
neous in terms of experience. As they did not care for 
one specific category of patients, it was not necessary to 
increase the sample size of these professionals.
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